2026 Q1 -tulosraportti
Vain PDF
42 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 600 | - | - | ||
| 3 518 | - | - | ||
| 4 200 | - | - | ||
| 134 755 | - | - | ||
| 27 355 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 544 989 | 2 544 989 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 544 989 | 2 544 989 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·56 min sittenRelevant considerations regarding Dicot Pharma's potential. I take the liberty of copying this from the Placera forum. …The post is made by Smart… Example of a present value calculation in Dicot Pharma The market approx 50 billion kr but that corresponds to what existing drugs sell for. Lib-01, judging by the Phase IIa study, has even greater market potential in a well-defined market with a new, more interesting mechanism of action, as the effect has proven to be significantly more lasting according to the Phase IIa outcome. The cash is secured for the entire Phase IIb study, it seems. It seems mostly required to first complete the Phase IIb study to secure good statistical significance for clinically meaningful effect with, as far as I interpret it, a monopoly on the new mechanism of action for a decade or so if no competitors exist with the same or similar mechanism of action. The calculation still feels reasonable as they are likely to be first. Total revenues during the patent period upon success for the one(s) owning Lib-1 can thus amount to many hundreds of billions kr. A share price of e.g. 1 kr corresponds to approx 3 billion in company value including dilution. The most likely scenario upon study success in Phase IIb, including during the study after interim data on outcomes, should be a licensing agreement after/during the Phase IIb study. Conservatively calculated with 10 % royalty on sales, say an average of 25 billion kr for 10 years (e.g. due to some remaining increased competition in the future) and simplified approximated that all revenues will come 5 years after market approval in 2031, i.e. 2036, then the present value, still ASSUMING success in/during Phase IIb FOR a licensing agreement, with an assumed discount rate of 15 % : 1 10 % x(10 years x 25 billion/year/(1+ 0.15)^10 = approx 6.18 billion kr. The present value per share upon success with a licensing agreement as specified above, with full dilution from warrants, then becomes approx 6.18/2.94 billion kr 2.10 kr. I assess that it is reasonable to assume that the market may discount a probability of e.g. 25 % for such success with currently very promising Phase IIa data in hand, without deeper mechanistic and competitive analysis. This would result in an estimated reasonable valuation on the stock market now of 0.25 x 2.10 kr = approx 0.44 kr. If the Phase IIb study yields further positive data that increases the probability of ultimate success, the share price can fundamentally be justified to rise more, all else being equal. With a higher royalty rate or the Phase III study under own management or some faster path to market, a higher share price can be justified at present. Everyone buys at their own risk, of course, with their own investment horizon. I suspect that there could be a really significant revaluation gradually over the next year as the rights issue "ghost" is now eliminated or has already been eliminated until data from Phase IIb comes from the very start of H2
1 päivä sitten1 päivä sitten
·1 päivä sittenGood news now at 4 PM, right? What do you think about the share price development in the near future? The research company Dicot Pharma announces that the rights issue of approximately 210 million kronor was subscribed to approximately 134 percent. A total of 207.2 million units were subscribed with and without preferential rights, which means that no issue guarantees need to be utilized.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
42 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·56 min sittenRelevant considerations regarding Dicot Pharma's potential. I take the liberty of copying this from the Placera forum. …The post is made by Smart… Example of a present value calculation in Dicot Pharma The market approx 50 billion kr but that corresponds to what existing drugs sell for. Lib-01, judging by the Phase IIa study, has even greater market potential in a well-defined market with a new, more interesting mechanism of action, as the effect has proven to be significantly more lasting according to the Phase IIa outcome. The cash is secured for the entire Phase IIb study, it seems. It seems mostly required to first complete the Phase IIb study to secure good statistical significance for clinically meaningful effect with, as far as I interpret it, a monopoly on the new mechanism of action for a decade or so if no competitors exist with the same or similar mechanism of action. The calculation still feels reasonable as they are likely to be first. Total revenues during the patent period upon success for the one(s) owning Lib-1 can thus amount to many hundreds of billions kr. A share price of e.g. 1 kr corresponds to approx 3 billion in company value including dilution. The most likely scenario upon study success in Phase IIb, including during the study after interim data on outcomes, should be a licensing agreement after/during the Phase IIb study. Conservatively calculated with 10 % royalty on sales, say an average of 25 billion kr for 10 years (e.g. due to some remaining increased competition in the future) and simplified approximated that all revenues will come 5 years after market approval in 2031, i.e. 2036, then the present value, still ASSUMING success in/during Phase IIb FOR a licensing agreement, with an assumed discount rate of 15 % : 1 10 % x(10 years x 25 billion/year/(1+ 0.15)^10 = approx 6.18 billion kr. The present value per share upon success with a licensing agreement as specified above, with full dilution from warrants, then becomes approx 6.18/2.94 billion kr 2.10 kr. I assess that it is reasonable to assume that the market may discount a probability of e.g. 25 % for such success with currently very promising Phase IIa data in hand, without deeper mechanistic and competitive analysis. This would result in an estimated reasonable valuation on the stock market now of 0.25 x 2.10 kr = approx 0.44 kr. If the Phase IIb study yields further positive data that increases the probability of ultimate success, the share price can fundamentally be justified to rise more, all else being equal. With a higher royalty rate or the Phase III study under own management or some faster path to market, a higher share price can be justified at present. Everyone buys at their own risk, of course, with their own investment horizon. I suspect that there could be a really significant revaluation gradually over the next year as the rights issue "ghost" is now eliminated or has already been eliminated until data from Phase IIb comes from the very start of H2
- 1 päivä sitten1 päivä sitten
- ·1 päivä sittenGood news now at 4 PM, right? What do you think about the share price development in the near future? The research company Dicot Pharma announces that the rights issue of approximately 210 million kronor was subscribed to approximately 134 percent. A total of 207.2 million units were subscribed with and without preferential rights, which means that no issue guarantees need to be utilized.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 600 | - | - | ||
| 3 518 | - | - | ||
| 4 200 | - | - | ||
| 134 755 | - | - | ||
| 27 355 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 544 989 | 2 544 989 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 544 989 | 2 544 989 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
2026 Q1 -tulosraportti
Vain PDF
42 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 30.4. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 | ||
2025 Q1 -tulosraportti 29.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·56 min sittenRelevant considerations regarding Dicot Pharma's potential. I take the liberty of copying this from the Placera forum. …The post is made by Smart… Example of a present value calculation in Dicot Pharma The market approx 50 billion kr but that corresponds to what existing drugs sell for. Lib-01, judging by the Phase IIa study, has even greater market potential in a well-defined market with a new, more interesting mechanism of action, as the effect has proven to be significantly more lasting according to the Phase IIa outcome. The cash is secured for the entire Phase IIb study, it seems. It seems mostly required to first complete the Phase IIb study to secure good statistical significance for clinically meaningful effect with, as far as I interpret it, a monopoly on the new mechanism of action for a decade or so if no competitors exist with the same or similar mechanism of action. The calculation still feels reasonable as they are likely to be first. Total revenues during the patent period upon success for the one(s) owning Lib-1 can thus amount to many hundreds of billions kr. A share price of e.g. 1 kr corresponds to approx 3 billion in company value including dilution. The most likely scenario upon study success in Phase IIb, including during the study after interim data on outcomes, should be a licensing agreement after/during the Phase IIb study. Conservatively calculated with 10 % royalty on sales, say an average of 25 billion kr for 10 years (e.g. due to some remaining increased competition in the future) and simplified approximated that all revenues will come 5 years after market approval in 2031, i.e. 2036, then the present value, still ASSUMING success in/during Phase IIb FOR a licensing agreement, with an assumed discount rate of 15 % : 1 10 % x(10 years x 25 billion/year/(1+ 0.15)^10 = approx 6.18 billion kr. The present value per share upon success with a licensing agreement as specified above, with full dilution from warrants, then becomes approx 6.18/2.94 billion kr 2.10 kr. I assess that it is reasonable to assume that the market may discount a probability of e.g. 25 % for such success with currently very promising Phase IIa data in hand, without deeper mechanistic and competitive analysis. This would result in an estimated reasonable valuation on the stock market now of 0.25 x 2.10 kr = approx 0.44 kr. If the Phase IIb study yields further positive data that increases the probability of ultimate success, the share price can fundamentally be justified to rise more, all else being equal. With a higher royalty rate or the Phase III study under own management or some faster path to market, a higher share price can be justified at present. Everyone buys at their own risk, of course, with their own investment horizon. I suspect that there could be a really significant revaluation gradually over the next year as the rights issue "ghost" is now eliminated or has already been eliminated until data from Phase IIb comes from the very start of H2
- 1 päivä sitten1 päivä sitten
- ·1 päivä sittenGood news now at 4 PM, right? What do you think about the share price development in the near future? The research company Dicot Pharma announces that the rights issue of approximately 210 million kronor was subscribed to approximately 134 percent. A total of 207.2 million units were subscribed with and without preferential rights, which means that no issue guarantees need to be utilized.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 17 600 | - | - | ||
| 3 518 | - | - | ||
| 4 200 | - | - | ||
| 134 755 | - | - | ||
| 27 355 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 544 989 | 2 544 989 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 544 989 | 2 544 989 | 0 | 0 |